Abstract
There is mixed evidence about how various personal characteristics contribute to the variability in survival in NSCLC patients after immunotherapy, as existing studies have substantial heterogeneity in clinical characteristics, tumor mutation expression, and line of therapy. Systematic reviews and meta-analyses frequently focus on randomized controlled trials (RCTs) which have limited generalizability, given their disproportionate enrollment of younger and healthier, male, and white patients in early lines of therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
